97 related articles for article (PubMed ID: 17219417)
1. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
Burkitt M; Magee C; O'Connor D; Campbell F; Cornford P; Greenhalf W
Mol Carcinog; 2007 Jun; 46(6):466-75. PubMed ID: 17219417
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin prevents nuclear translocation of mutant p53.
Dasgupta G; Momand J
Exp Cell Res; 1997 Nov; 237(1):29-37. PubMed ID: 9417863
[TBL] [Abstract][Full Text] [Related]
5. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
Lesko E; Gozdzik J; Kijowski J; Jenner B; Wiecha O; Majka M
Anticancer Drugs; 2007 Nov; 18(10):1173-81. PubMed ID: 17893518
[TBL] [Abstract][Full Text] [Related]
6. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
Hanson BE; Vesole DH
Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
[TBL] [Abstract][Full Text] [Related]
7. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
8. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
McNamara AV; Barclay M; Watson AJ; Jenkins JR
Biochem Pharmacol; 2012 Feb; 83(3):355-67. PubMed ID: 22138446
[TBL] [Abstract][Full Text] [Related]
10. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
Crèvecoeur J; Merville MP; Piette J; Gloire G
Biochem Pharmacol; 2008 Jun; 75(11):2183-91. PubMed ID: 18455150
[TBL] [Abstract][Full Text] [Related]
11. Indirect participation of Hsp90 in the regulation of the cyclin E turnover.
Bedin M; Catelli MG; Cabanié L; Gaben AM; Mester J
Biochem Pharmacol; 2009 Jan; 77(2):151-8. PubMed ID: 18977205
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
16. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
18. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
19. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
Li X; Deng HY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
[TBL] [Abstract][Full Text] [Related]
20. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
